Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNCA54
|
|||
| Drug Name |
CLR 131
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Waldenstrom macroglobulinemia [ICD-11: 2A85.4; ICD-10: C88.0; ICD-9: 273.3] | Phase 2 | [1] | |
| Head and neck cancer [ICD-11: 2D42; ICD-9: 199] | Phase 1 | [2] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [3] | ||
| Company |
Cellectar Biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02952508) Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04105543) CLR 131 Combined With Radiation for Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.